Generic semaglutide, the active ingredient in Ozempic, is now available in Canadian pharmacies and through digital prescription platforms.
This rollout marks a shift in the accessibility of weight-loss and diabetes medications in Canada. By introducing generic alternatives, the healthcare system can reduce the financial burden on patients who previously relied on more expensive brand-name versions.
Apotex, Dr. Reddy's, and Hims & Hers Health are the providers offering the generic version of the medication [1]. The drug is available as a once-weekly treatment [2]. While Health Canada approved the generic version about three weeks before early May, the medication officially became available via the Hims & Hers digital platform on May 21, 2026 [3, 4].
The path to generic approval followed the expiry of the original patent held by Novo Nordisk. According to reports, Novo Nordisk did not pay a required C$250 annual fee [5]. This administrative lapse allowed Health Canada to move forward with the approval of generic versions to lower costs for the public [5].
Patients can now access the medication through traditional brick-and-mortar pharmacies, or via digital health services [6]. The availability of digital prescriptions allows for a streamlined process in obtaining the drug, expanding reach beyond physical clinic locations [7].
“Generic semaglutide is now available in Canadian pharmacies and through digital prescription platforms.”
The entry of generic semaglutide into the Canadian market removes a significant cost barrier for a high-demand medication. The fact that a missed C$250 fee accelerated this process highlights the fragility of patent protections when administrative requirements are not met, potentially setting a precedent for how other brand-name drugs are transitioned to generics in Canada.
